Joint Action


Sex and gender differences in osteoarthritis with Dr Melissa Laitner

Season 2, Ep. 4

Osteoarthritis places a large burden on the individuals that are affected as well is to society as a whole. It is important to reflect that that burden is not distributed equally. The prevalence of osteoarthritis is higher amongst women compared to men. Women also experience higher rates of disease severity and disability. In an effort to better understand these disparities with the overarching focus being to improve health outcomes for all it is important to understand the influence of sex and gender differences in osteoarthritis research and clinical care.

Melissa Laitner, PhD, MPH is Director of Public Policy and Government Affairs at the Society for Women’s Health Research, a Washington, D.C. based non-profit with a goal of improving health care for women through science, policy, and education. At SWHR, Laitner manages all regulatory and legislative efforts, transforming the work of SWHR’s scientific experts into tangible, evidence-based policy recommendations. Prior to joining SWHR, Laitner worked as an American Association for the Advancement of Science health policy fellow in the office of Senator Michael Bennet (D-CO). In this role, she worked on a wide-ranging portfolio with an emphasis on matters related to CMS, FDA, prescription drugs, mental health, and topics relevant to health care transparency, costs, and coverage. Before entering the policy field, Laitner worked as a clinical health psychologist at a large academic medical center. She remains a licensed clinical psychologist in the District of Columbia.


Journal articles


If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

More Episodes


The burden of osteoarthritis with Prof Gillian Hawker

Season 2, Ep. 5
The impact of osteoarthritis remains a major challenge for healthcare systems worldwide with approximately 528 million people affected. The global prevalence of hip and knee OA is approaching 5% and expected to increase further with the aging population. The increasing rates of obesity in adults, combined with lack of physical activity and joint injuries are also contributing to the rise in OA incidence. Osteoarthritis is a serious condition which has substantial implications on one’s day-to-day functioning. It is associated with other diseases such as high blood pressure, high cholesterol and back pain all of which leads to an increase in mortality. Dr. Gillian Hawker is Professor of Medicine in the Department of Medicine, Division of Rheumatology, at the University of Toronto. She is active staff in Rheumatology at Women’s College Hospital, where she is a clinician-scientist at the Women’s College Research Institute. She is a senior scientist at the Institute for Health Policy, Management and Evaluation and adjunct senior scientist at the Institute for Clinical Evaluative Sciences. In July 2014, she was appointed the Sir John and Lady Eaton Professor and Chair of the Department of Medicine at the University of Toronto (U of T).RESOURCESOARSI white paper - osteoarthritis as a serious diseaseCONNECT WITH GILLIANTwitter: @UofTDoMChairEmail: g.hawker@utoronto.caCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

New insights into osteoarthritis onset with Prof Frank Beier

Season 2, Ep. 3
Despite the large prevalence of osteoarthritis, there is no clinically approved drug which provides a cure. Currently, drugs focus on relieving symptoms such as pain. Experiments done in the laboratory have provided insight on osteoarthritis onset and progression and will likely guide therapeutic development. We know that osteoarthritis is a disease of the whole organ meaning that any of the tissues involved in the synovial joint can be affected. The interplay between the various cell types involved is complex and understanding the interactions between cartilage, bone and synovium may be critical to therapeutic development.Skeletal development likely plays a very important role in predisposition to disease. Through the identification of serious pathologies such as various forms of dwarfism (what in medical terms are called chondrodysplasias) the role of transcription factors and epigenetics is increasing our understanding of disease genesis.The study of the epigenetics of OA - the mechanism by which the human genome alters it’s gene expression (without changing the primary DNA sequence) has provided valuable information on novel risk factors for the disease and are potential therapeutic targets for OA. On today's show, Dr Frank Beier joins us to discuss the recent advances in osteoarthritis understanding with a particular emphasis on novel targets and epigenetics. Frank Beier is the Canada Research Chair in Musculoskeletal Research at the University of Western Ontario and a member of Western’s Bone and Joint Institute. He is a Professor and Chair of the Department of Physiology and Pharmacology. His lab explores mechanisms controlling cartilage and joint biology, using genetically engineered mice in combination with surgical, dietary and activity manipulations. This is a natural fit with the objectives of the Bone and Joint Institute, an environment that has helped to foster collaborations with fellow researchers from other fields such as clinicians (surgeons, rheumatologists) and imaging scientists. As an engaged member of the Institute’s Operations Committee, Dr. Beier sees value in Institute priorities that improve his training program and that support the acquisition of additional research funds. Dr. Beier has published over 100 peer-reviewed articles and gave 100 invited presentations. His work is supported by the Canadian Institutes of Health Research (from which he won a foundation award in the inaugural competition in 2015) and The Arthritis Society. He was a member of the Board of Directors of the Osteoarthritis Research Society Internationaland several editorial boards, including the Deputy Editor for Osteoarthritis & Cartilage. He was the Chair of the 2017 Cartilage Gordon Conference and won the OARSI Basic Science award in 2019. RESOURCESJournal articlesNuclear receptors as potential drug targets in osteoarthritisInterplay between genetics and epigenetics in osteoarthritisRecent developments in emerging therapeutic targets of osteoarthritisCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

What type of osteoarthritis do I have? with Prof Francis Berenbaum

Season 2, Ep. 2
There are many reasons why osteoarthritis (OA) might develop in the first place, the progression of the disease can vary dramatically between different individuals and their response to different treatments can similarly be quite distinct. With the greater understanding OA pathophysiology, OA can often be described as a spectrum of disease composed of different phenotypes. Some people have even described this as a mixed bag of disorders or falling under the osteoarthritis umbrella. By characterising OA into phenotypes, it helps to improve our knowledge of the disease, and ultimately enables targeted treatment based on the phenotype that a patient presents with. On this episode of Joint Action, we will be speaking to Dr Francis Berenbaum to learn more about osteoarthritis phenotypes, how they are identified and how this affects the management of OA. Dr. Berenbaum is Professor of rheumatology at Sorbonne Université and is the Director of the Department of Rheumatology at AP-HP Saint-Antoine Hospital in Paris, France. He is the national representative of bone and joint diseases at AVIESAN, the French Alliance for the Life Science and Health. He is a member of the EULAR Public Affairs Group and is a former member of the EULAR Scientific Program committee in 2018-2020. He is a former president of OARSI (Osteoarthritis Research Society International) in 2008-2010 and of the French Society of Rheumatology in 2014-2016. He is Associate Editor of the Annals of the Rheumatic Diseases. Dr Berenbaum leads an experimental team at INSERM institute. His basic research interests include the understanding of relationships between metabolic diseases and osteoarthritis. His clinical research focuses on new targeted therapies for treating symptoms and structural changes in osteoarthritis. He is involved in several clinical trials either from public or private partners. He has published more than 300 peer-reviewed publications.RESOURCESJournal articlesOsteoarthritis and inflammation: a serious disease with overlapping phenotypic patternsThe Phenotypic Approach to Osteoarthritis: A Look at Metabolic Syndrome-Associated OsteoarthritisDeep phenotyping of osteoarthritis: a step forwardCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!